NYSE: ENZEnzo Biochem Inc Stock
$0.31-0.07 (-18.42%)
Updated Apr 17, 2025
ENZ Price
$0.31
Fair Value Price
N/A
Market Cap
$16.45M
52 Week Low
$0.25
52 Week High
$1.28
P/E
-0.75x
P/B
0.35x
P/S
1.09x
PEG
N/A
Dividend Yield
31.85%
Revenue
$29.10M
Earnings
-$21.31M
Gross Margin
44.7%
Operating Margin
-69.87%
Profit Margin
-73.2%
Debt to Equity
0.45
Operating Cash Flow
-$15M
Beta
0.64
Next Earnings
Jun 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ENZ Overview
Enzo Biochem, Inc. manufactures and sells diagnostic and research products based on genetic engineering, biotechnology, and molecular biology to clinical laboratories, researchers, and physicians in the U.S. and internationally. Offerings include proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits used for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. Enzo Biochem was founded in 1976 and is headquartered in Farmingdale, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ENZ's potential to beat the market
- ENZ doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
ENZ
RankedUnranked of 45
RankedUnranked of 45
Be the first to know about important ENZ news, forecast changes, insider trades & much more!
ENZ News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ENZ scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENZ is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ENZ is good value based on its book value relative to its share price (0.35x), compared to the US Diagnostics & Research industry average (3.26x)
P/B vs Industry Valuation
ENZ is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 35 more ENZ due diligence checks available for Premium users.
Valuation
ENZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.75x
Industry
36.04x
Market
27.98x
ENZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.35x
Industry
3.26x
ENZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENZ's financial health
Profit margin
Revenue
$7.3M
Net Income
-$1.5M
Profit Margin
-20.9%
ENZ's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ENZ's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$67.5M
Liabilities
$20.9M
Debt to equity
0.45
ENZ's short-term assets ($52.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENZ's short-term assets ($52.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENZ's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ENZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
-$70.0k
Financing
-$5.3M
ENZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENZ vs Diagnostic & Research Stocks
Enzo Biochem Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.